Completed PHASE2 INTERVENTIONAL 1-arm NCT00919282

Gemcitabine (GFF) in Patients With Pancreatic Cancer (GFF)

A Multi Center Phase II Study of 5-Fluorouracil/ Folinic Acid Plus Gemcitabine in Patients With Advanced Pancreatic Cancer.

Sponsor: CONKO-Studiengruppe

Conditions Metastatic Pancreatic Cancer

Interventions gemcitabine, folinic acid, 5-FU

Updated 5 times since 2017 Last updated: Jun 11, 2009 Started: Sep 30, 1997 Primary completion: Jul 31, 2000 Completion: Dec 31, 2002

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Metastatic Pancreatic Cancer, this trial is completed. The trial is conducted by CONKO-Studiengruppe and has accumulated 5 data snapshots since 1997. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Sep 1997

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

CONKO-Studiengruppe
Eli Lilly and Company

Data source: CONKO-Studiengruppe

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Berlin, Germany